Bristol Myers Squibb Stock Surges Following Success in Pair of Late-Stage Drug Studies
Bristol Myers Squibb Company (NYSE:BMY) equity gained almost 6% in pre-market activity on Monday after releasing favorable preliminary findings from two late-stage clinical studies. The pharmaceutical manufacturer achieved key milestones in research aimed at treating a chronic respiratory illness and digestive tract cancers.
In the ALOFT-IPF study testing admilparant for idiopathic pulmonary fibrosis, a 60 mg daily measure successfully hit its main target by demonstrating a noticeable rise in lung capacity at 52 weeks relative to a control group. A higher 120 mg dosage helped lessen lung function loss, though that result fell short of statistical significance.
Meanwhile, a second Phase 3 study designated ACTION-1 evaluated RYZ101 in individuals with advanced neuroendocrine tumors affecting the digestive system who had previously failed lutetium-177 treatment. The candidate met its primary goal, prolonging the duration patients lived without cancer advancement, while safety observations aligned with prior findings for the therapy.
Key points
- Bristol Myers Squibb equity climbed almost 6% early Monday after announcing positive Phase 3 clinical trial outcomes.
- The 60 mg dose of admilparant successfully increased lung capacity over 52 weeks in idiopathic pulmonary fibrosis patients.
- A 120 mg admilparant dose slowed lung function loss but lacked statistical significance.
- RYZ101 extended progression-free survival in late-stage neuroendocrine tumor patients previously treated with lutetium-177.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Bristol Myers Squibb stock increase on Monday?
Shares rose nearly 6% in premarket trading after the pharmaceutical firm announced that two separate Phase 3 clinical trials had achieved their main endpoints.
What were the key results from the ALOFT-IPF clinical trial?
The 60 mg admilparant dose achieved its main goal by improving 52-week forced vital capacity compared to placebo. A higher dose slowed decline without reaching statistical significance.
How did RYZ101 perform in the ACTION-1 study?
The trial met its primary objective by significantly lengthening progression-free survival in patients with advanced neuroendocrine tumors who previously received lutetium-177.